Overview: TORCH RT PCR TestIntroduction: The TORCH RT PCR Test detects TORCH pathogens via RT-PCR to diagnose active infections, causing fever. Aligned with 2023 ACOG guidelines, it uses RT-PCR for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected active TORCH infections. Note: No specific test parameters provided in input data.
Other Names: TORCH RT-PCR Assay, Congenital Infection RT-PCR Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: TORCH RT-PCR testing began in the 2000s with viral detection research. RT-PCR methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects TORCH pathogens via RT-PCR to diagnose active infections, guides treatment, and evaluates patients with fever.
Test Parameters: Not specified in input data; typically includes RNA of TORCH pathogens.
Pretest Condition: No fasting required. Collect whole blood, serum, plasma, CSF, or saliva. Report history of fever or TORCH infection symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), CSF (sterile container, 1-2 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fever, rash, or history of TORCH infections. Include current medications, especially antivirals.
Consent: Written consent required, detailing the tests purpose, TORCH infection implications, and risks of sample collection.
Procedural Considerations: Uses real-time PCR to detect RNA of TORCH pathogens (Toxoplasma, Rubella, CMV, HSV). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for active infection diagnosis.
Factors Affecting Result Accuracy: Low RNA yield or contamination can affect results. Sample quality impacts specificity.
Clinical Significance: Positive TORCH RNA confirms active infection, guiding antiviral therapy. Negative results may require serology or culture.
Specialist Consultation: Consult an infectious disease specialist or neonatologist for result interpretation and treatment planning.
Additional Supporting Tests: TORCH serology, viral culture, or clinical evaluation to confirm active infection diagnosis.
Test Limitations: Specific to detectable pathogens; clinical correlation is needed. Sample quality affects sensitivity.
References: ACOG Congenital Infection Guidelines, 2023; Clinical Infectious Diseases, Navas-Nacher V, 2022.
